

**FACSIMILE TRANSMITTAL**

February 4, 2003

**from HOLLY D. KOZLOWSKI**

Direct: 513-977-8568 / Fax: 513-977-8141 / holly.kozlowski@dinslaw.com

**To:** Group Art Unit 1644; Examiner P. Nolan**Firm:** U.S. Patent & Trademark Office (USPTO)**Fax Number:** 703-308-2742**FAX RECEIVED****Client Number:** 10806-93

FEB 5 2003

3 17

**Pages:** 6  
(including cover)**GROUP 1600****Comments:****OFFICIAL**

If there are any problems in receiving this transmission, please call the fax room at (513) 977-8483 immediately. Thank you.

**Notice**

This message is intended only for the use of the individuals or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this notice in error, please notify us immediately by telephone and return these papers to us at the address below via first class mail.

Docket No. 10806-93

PATENTCERTIFICATE OF FACSIMILE

I hereby certify that this paper is being transmitted via facsimile to Group Art Unit 1644, Examiner P. Nolan; Box AF; Commissioner of Patents; Washington, DC 20231, at facsimile number 703-308-2742 on February 4, 2003.

Expedited Processing  
Amendment Under 37 CFR 1.116

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:	Reto CRAMERI et al	Paper No.:
Serial No.:	09/319,806	Group Art Unit: 1644
Filed:	August 19, 1999	Examiner: P. Nolan
For: Methods for Diagnosis of Allergic Bronchopulmonary Aspergillosis		

Box AF  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an Amendment Under 37 CFR 1.116 in the above identified application.

No additional fee is required.  
 Also attached:

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUS PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	17	20	0	x \$18 =	-
Independent Claims	4	5	0	x \$84 =	-
<b>TOTAL FEE DUE</b>					<b>\$0</b>

- A check in the amount of \$0 is enclosed.
- Please charge my Deposit Account No. 04-1133 in the amount of \$0.
- The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment, to Deposit Account No. 04-1133, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Holly D. Kozlowski  
Registration No. 30,458

DINSMORE & SHOHL LLP  
1900 Chemed Center  
255 East Fifth Street  
Cincinnati, Ohio 45202  
(513) 977-8686  
Date: February 4, 2003

667125.01

# 19/F  
GRD 2/5/03  
PATENT  
N.E.

Docket No. 10806-93

CERTIFICATE OF FACSIMILE

I hereby certify that this paper is being transmitted via facsimile to Group Art Unit 1644, Examiner P. Nolan; Box AF; Commissioner of Patents; Washington, DC 20231, at facsimile number 703-308-2742 on February 4, 2003.

Expedited Processing  
Amendment Under 37 CFR 1.116

Lauren E. Main

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:	Reto CRAMERI et al	:	Paper No.:
Serial No.:	09/319,806	:	Group Art Unit: 1644
Filed:	August 19, 1999	:	Examiner: P. Nolan
For:	Methods for Diagnosis of Allergic Bronchopulmonary Aspergillosis		

AMENDMENT UNDER 37 C.F.R. 1.116

Box AF  
Commissioner for Patents  
Washington, DC 20231

Dear Sir:

In response to the Official Action dated November 4, 2002, please amend the present application as follows:

*Do not  
cancel  
claims  
P.N.  
2/4/03*

In the Claims:

Please cancel claims 1-3.

Please amend claims 6-8 to read as follows:

6. (Twice Amended) The method according to claim 4, wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens.

7. (Twice Amended) The method according to claim 4, wherein antibodies of the IgE class are determined.